Skip to main content

Table 1 Demographic and clinical characteristics of enrolled patients at COVID-19 diagnosis

From: COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

  n %
Sex
Female 1579 41.5
Male 2222 58.5
Age, median (IQR) [range] 65 (54–74), [18–95]
Comorbidities
Chronic cardiopathy 1146 30.1
Chronic pulmonary disease 614 16.2
Diabetes mellitus 620 16.3
Liver disease 167 4.4
Obesity 345 9.1
Renal impairment 325 8.6
Smoking history 477 12.5
No risk factor identified 1463 38.5
Baseline hematological malignancies
Acute lymphoid leukemia 169 4.4
Chronic lymphoid leukemia 474 12.5
Acute myeloid leukemia 497 13.1
Chronic myeloid leukemia 161 4.2
Myelodysplastic syndrome 279 7.3
 Low-intermediate risk 138 3.6
 High risk 48 1.3
 Not stated 93 2.4
Hairy cell leukemia 23 0.6
Hodgkin lymphoma 135 3.6
Non-Hodgkin lymphoma 1084 28.5
 Indolent 497 13.1
 Aggressive 516 13.6
 Not stated 71 1.9
Essential thrombocythemia 69 1.8
Myelofibrosis 122 3.2
Polycythemia vera 70 1.8
Systemic mastocytosis 6 0.2
Multiple myeloma 684 18.0
Amyloidosis 8 0.2
Aplastic anemia 20 0.5
Statusa
Controlled disease 1760 46.3
Complete remission 1170 30.8
Partial remission 590 15.5
Active disease 1963 51.6
Onset 888 23.4
Refractory/Resistant 473 12.4
Stable disease 524 13.8
Unknown 78 2.1
Unknown 78 2.1
  1. Data can be super additive
  2. aOnset patients had a contemporaneous diagnosis of the malignancy and the COVID-19, regardless of malignancy treatment initiation. Stable disease patients include patients at watch and wait